# An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics

> **NCT00870454** · PHASE2 · COMPLETED · sponsor: **SK Life Science, Inc.** · enrollment: 386 (actual)

## Conditions studied

- Diabetic Neuropathies

## Interventions

- **DRUG:** Pregabalin 300 mg/d
- **DRUG:** Carisbamate 800 mg/d
- **DRUG:** Carisbamate 1,200 mg/d
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00870454
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 386 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00870454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00870454, "An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00870454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*